Trial Profile
A 24-week Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HMS5552 With Additional 28-week Open-label Treatment to Evaluate the Safety of HMS5552 Alone in T2DM Subjects
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Dorzagliatin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SEED
- Sponsors Hua Medicine
- 07 Jun 2022 Results of post hoc analysis of two phase III clinical trials (NCT03173391 and NCT03141073), evaluating the correlation between glycemic control and the restoration effect of glucokinase activator on beta cell cell function presented at the 82nd Annual Scientific Sessions of the American Diabetes Association
- 01 May 2022 Results published in the Nature Medicine
- 29 Jun 2021 Results presented at the 81st Annual Scientific Sessions of the American Diabetes Association